| Cash Flow | 2026-03-31 |
|---|---|
| Net loss | -10,331 |
| Stock-based compensation | 4,069 |
| Depreciation and amortization | 243 |
| Prepaid and other current assets | -867 |
| Accounts payable and accrued expenses | -2,458 |
| Accrued development expense | 241 |
| Accrued compensation and benefits | -1,379 |
| Other liabilities | -130 |
| Net cash used in operating activities | -8,878 |
| 2025 atm program offering costs | 51 |
| Proceeds from issuance of common stock upon exercise of stock options | 0 |
| Net cash (used in) provided by financing activities | -51 |
| Net decrease in cash and cash equivalents | -8,929 |
| Cash and cash equivalents at beginning of period | 95,502 |
| Cash and cash equivalents at end of period | 86,573 |
FILANA THERAPEUTICS, INC. (FLNA)
FILANA THERAPEUTICS, INC. (FLNA)